Celltrion participated in the 2025 BIO International Convention in Boston from June 16th to 19th (local time), taking part in the world's largest biotech industry event to expand strategic collaborations with global pharmaceutical and biotech companies.
Having attended BIOUSA for the 16th consecutive year, Celltrion held over 150 business meetings during the event, engaging in in-depth discussions on its biosimilars, pipeline of new drug candidates, contract development and manufacturing organization (CDMO), and open innovation initiatives.
The company notably focused on exploring collaboration opportunities around its current pipeline of drug candidates, including antibody-drug conjugates (ADCs), multi-specific antibodies, novel antibody therapies, and peptides. According to officials, these technology-centered partnerships aim to strengthen their new drug development capabilities and lay a solid foundation for transitioning into a major global new drug innovator.
Celltrion also actively advanced open innovation activities. The company held discussions with promising biotech startups and research institutes to broaden its access to cutting-edge technologies, with plans to follow up with potential partners for further evaluation and collaboration.
Efforts to strengthen distribution channels also drew attention. As Celltrion sells its biosimilar products directly in major markets such as Europe and North America, the company received numerous requests for cooperation related to logistics and warehousing. In some indirect sales countries, discussions on expanding existing distribution partnerships were also underway.
At the exhibition booth, the company distributed product brochures along with digital content accessed via QR codes, and hosted a souvenir giveaway event for visitors. During the event, more than 1,800 attendees visited Celltrion’s booth.
A Celltrion representative stated, “This year, there was heightened interest in our efforts to expand into the innovative new drug sector,” adding, “We will continue to strengthen our competitiveness in the global novel drug market through ongoing technological alliances and strategic partnerships.”
